Dr. Jonasch on the Future of Belzutifan in Clear Cell RCC

Video

In Partnership With:

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma (RCC).

Positive data from the phase 1 LITESPARK-001 trial (NCT02974738) led to the randomized phase 3 LIGHTSPARK-005 trial (NCT05239728), which has already completed accrual, Jonasch says. LIGHTSPARK-005 is investigating belzutifan plus pembrolizumab (Keytruda) vs pembrolizumab plus placebo in patients with clear cell RCC post nephrectomy.

There are multiple studies examining belzutifan in combination with either immunotherapy or TKIs, so there are various routes being explored to find a place for it in the treatment paradigm for RCC, Jonasch explains. However, clinicians still need to determine exactly the best way is to utilize it, whether as a single agent or part of a combination, though both options are realistic possibilities, Jonasch concludes.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Chul Kim, MD, MPH